INAB · In8bio, Inc.

Substantial doubt about the company's ability to continue as a going concern.

“Based on the Company's business strategy, its existing cash of $18.0 million as of June 30, 2026 is not anticipated to fund the Company's projected operating expenses and capital expenditure requirements for a period of at least 12 months from the date of issuance of these condensed financial statements, and accordingly, there is substantial doubt about the Company's ability to continue to operate as a going concern.”